JP2014523906A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523906A5
JP2014523906A5 JP2014519502A JP2014519502A JP2014523906A5 JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5 JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5
Authority
JP
Japan
Prior art keywords
administered
drug
defensins
agent
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519502A
Other languages
English (en)
Japanese (ja)
Other versions
JP6219277B2 (ja
JP2014523906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063137 external-priority patent/WO2013007596A2/en
Publication of JP2014523906A publication Critical patent/JP2014523906A/ja
Publication of JP2014523906A5 publication Critical patent/JP2014523906A5/ja
Application granted granted Critical
Publication of JP6219277B2 publication Critical patent/JP6219277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519502A 2011-07-08 2012-07-05 炎症性腸疾患の経口治療 Active JP6219277B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11173351.5 2011-07-08
EP11173351 2011-07-08
US201161506437P 2011-07-11 2011-07-11
US61/506,437 2011-07-11
PCT/EP2012/063137 WO2013007596A2 (en) 2011-07-08 2012-07-05 Oral treatment of inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008251A Division JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Publications (3)

Publication Number Publication Date
JP2014523906A JP2014523906A (ja) 2014-09-18
JP2014523906A5 true JP2014523906A5 (enExample) 2015-08-20
JP6219277B2 JP6219277B2 (ja) 2017-10-25

Family

ID=47506622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519502A Active JP6219277B2 (ja) 2011-07-08 2012-07-05 炎症性腸疾患の経口治療
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Country Status (5)

Country Link
US (3) US9217021B2 (enExample)
EP (1) EP2729159B1 (enExample)
JP (2) JP6219277B2 (enExample)
ES (1) ES2637286T3 (enExample)
WO (1) WO2013007596A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247591A (zh) 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
KR101590452B1 (ko) 2015-05-20 2016-02-02 중앙대학교 산학협력단 펩타이드 defb124를 유효성분으로 포함하는 면역증강 및 암 예방 또는 치료용 약학적 조성물
WO2017027411A1 (en) * 2015-08-07 2017-02-16 The Regents Of The University Of California Compositions and methods for inhibiting pro-inflammatory cytokine gene expression
WO2017129195A1 (en) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
BR112018071972A2 (pt) 2016-04-29 2019-02-26 Defensin Therapeutics Aps métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
EP3552632B1 (en) 2016-12-07 2023-07-12 Stelic Institute & Co., Inc. Medicinal composition for treating and preventing inflammatory bowel disease
US11413328B2 (en) 2016-12-13 2022-08-16 Novozymes A/S Methods for treating inflammatory conditions of the lungs
CA3082288A1 (en) * 2017-11-10 2019-05-16 Defensin Therapeutics Aps Maturation of mucosal defense and gut/lung function in the preterm infant
AU2018371948A1 (en) * 2017-11-24 2020-06-11 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
AU2019356916B2 (en) 2018-10-09 2022-12-01 The University Of Southern California Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE19824484A1 (de) * 1998-06-02 1999-12-09 Bayer Ag Festkörperreiche Polyurethandispersionen mit hoher Applikationssicherheit
DE19957043A1 (de) 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
AU2003288507A1 (en) 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
CA2704726A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent
AR072524A1 (es) 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
CN102247591A (zh) * 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
US8232248B2 (en) 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
AU2009292555B2 (en) * 2008-09-10 2014-05-29 AGC Inc. Novel prostaglandin I2 derivative
JP2011121887A (ja) * 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP4620169B1 (ja) * 2010-01-28 2011-01-26 株式会社三和化学研究所 有機酸重合体を有効成分とするクローン病の予防又は治療剤
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide

Similar Documents

Publication Publication Date Title
Liang et al. Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms
JP2012502113A5 (enExample)
Tao et al. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin
Pham et al. Strategies for the design of orally bioavailable antileishmanial treatments
Wang et al. Role of crosstalk between glial cells and immune cells in blood-brain barrier damage and protection after acute ischemic stroke
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
US10653669B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
Wang et al. Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease
AR081948A2 (es) USO DE b DEFENSINAS DE MAMIFEROS PARA LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL INTESTINO
JP2020516615A5 (enExample)
JP2013544244A5 (enExample)
JP2011520980A5 (enExample)
Sagnak et al. Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Guérin Treatment in Non–Muscle-Invasive Bladder Tumors
Goh et al. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine
US20210038696A1 (en) Rectal insulin for treatment of inflammatory bowel diseases
Khiong et al. Inhibition of NF-κB pathway as the therapeutic potential of red fruit (Pandanus conoideus Lam.) in the treatment of inflammatory bowel disease
WO2016150151A1 (zh) 青蒿琥酯在制备治疗中晚期脓毒症药物中的运用
Belhadjali et al. Sweet's syndrome associated with multiple myeloma
CN102488699A (zh) 芍药苷在制备防治肺纤维化药物中的应用
Gao et al. Tripterygium wilfordii polyglycosidium ameliorates pouchitis induced by dextran sulfate sodium in rats
Vaishnavi Management of Recurrent Apthous stomatitis-A Review
Hong et al. Annular leukocytoclastic vasculitis in a patient with ulcerative colitis
CN113209104B (zh) Jak3抑制剂在制备治疗急性呼吸窘迫综合症药物中的应用
Fernandes et al. Paradoxical skin reaction with infliximab treatment
Zhai et al. Inflammatory Dermatosis in HIV/AIDS Patients